Chronic hepatitis C in patients with cirrhosis compensation not receiving interferon or reoccurrence of interferon alpha-2b therapy: Co-administered with interferon alpha-2b or peginterferon alpha-2b. This phase is effective for HCV-HIV co-infection.
Several kinds of viral haemorrhagic fevers: Lassa fever, Haemorrhagic fevers with renal syndrome, pulmonary syndrome, Crimean-Congo haemorrhagic fevers.
Chronic hepatitis C: Ribavirin is used with interferon for oral use:
- Adults: 800 mg/day, in two divided doses. Dose adjustment depends on body-weight (up to 1200 mg/day for those > 85 kg)
- Children > 3 years of age: 15 mg/kg body-weight/day, in two divided doses.
Ribavirin is always used with interferon (3 – 5 million IU, injected 3 times a week) or peginterferon (1.5 µg/kg, injected once a week).
In those with hepatitis C infection alone (mono-infection), patients with viral genotype 1, 4: should generally be treated for 48 weeks and those with genotype 2 or 3 for 24 weeks; data on genotypes 5 or 6 are insufficient to make recommendations. In co-infection with HIV, treatment should generally be given for 48 weeks regardless of genotype.
In cases of reoccurrence treated with interferon: Continue the treatment with ribavirin within 24 weeks. Discontinuation of therapy should be considered if the patient has failed to detect HCV RNA levels after 24 weeks of therapy.
- Haemorrhagic fevers (Lassa fever, viral fever):
- Prophylaxis: Adults with risk of high exposure: Orally use 500 – 600 mg, with 6-hour-interval for 7 – 10 days.
Children 6 – 9 years of age: Orally use 400 mg, with 6-hour-interval for 7 – 10 days. Children < 6 years of age, doses have not been determined.
Ribastad 200 is administered orally twice a day, regardless of meals. However, ribavirin is absorbed better after taking fatty-meals.